Balanced charging of each cell in a battery pack is critical to meeting system requirements and maximising lifespan, while ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...